316
antineoplastic agent, as a model drug. The results of loading and release studies
were similar to the previously reported literature. Herein the introduction of the
molecular docking technique establishes a method to fast select an effective
β-cyclodextrin-based surface coating for the development of high-performance
magnetic nanoparticles (Chen et al. 2019).
During the last decade, researchers published numerous designings and preparation techniques of cyclodextrin-functionalized superparamagnetic nanoparticles by
conjugating cyclodextrin units onto the surface of magnetite nanoparticles.
Similarly, in one of the notable contributions, Lu and co-workers have explained an
innovative protocol for the development of cyclodextrin-based magnetic nanoparticles intending to establish their wide variety of biomedical applications as targeted
drug delivery vehicles. Briefly, Li et al. (2011) fabricated superparamagnetic
β-cyclodextrin-functionalized composite nanoparticles with core-shell compositions via cross-linking reaction (by using epichlorohydrin as cross-linking agent) on
the surface of carboxymethyl β-cyclodextrin-modified magnetite nanoparticles.
This strategy ensures that the innermost magnetite nanoparticles could sense and
react to an externally applied magnetic field. Additionally, the outermost cyclodextrin moiety represents an inclusion site for drugs. Luo et al. (2012) developed a
novel redox responsive controlled drug release system based on magnetic nanoparticles to provide efficient intracellular anticancer drug delivery. Disulfide bonds are
employed as intermediate linkers to immobilize polyethylenimine/β-cyclodextrin
molecules as nanoreservoirs for drug loading onto magnetic nanoparticles. The
endocytotic pathway and endosomal escape of the smart controlled drug release
system are proposed as an end result. Badruddoza et al. (2013) synthesized highly
uniform silica-coated iron oxide (Fe 3 O 4 ) magnetic nanoparticles and cross-linked
them with carboxymethylated-β-cyclodextrin, intending to equip magnetic nanoparticles with drug storage and delivery carrier. These magnetic nanoparticles contributed quadruple features of magnetism, luminescence, cell targeting, and hydrophobic
drug delivery. These magnetic nanoparticles included functionalities of fluorescence
labeling by fluorescent dye-conjugated and a common cancer-targeting ligand, folic
acid, that Banerjee’s magnetic nanoparticles lacked. Preliminary outcomes of this
study recommend that such magnetic nanoparticles can be a smart theranostic candidate for an optically trackable, cancer cell-targeting, and delivery vehicle of the
hydrophobic drug delivery (all-trans-retinoic acid), loaded in cyclodextrin moiety.
Ding et al. (2015) developed a novel hydrogel of poorly soluble drug 5-fluorouracil,
based on chitosan-cross-linked carboxymethyl-β-cyclodextrin polymer-modified
Fe 3 O 4 magnetic nanoparticles intending to explore the inclusion abilities of cyclodextrin hydrophobic cavity with this insoluble anticancer drug through host-guest
interactions. Experimental results showed that the nanocarriers displayed a high
loading efficiency and pH-dependent swelling and diffusion-controlled drug release.
This report tentatively proposed the mechanism of 5-fluorouracil encapsulated into
the magnetic chitosan nanoparticles.
The literature reveals that the Food and Drug Administration has approved more
than 150 chemotherapeutic agents for cancer treatment. But, most of these drugs
exert cytotoxic action on tumors as well as normal cells and cause severe adverse
A. Pandey
antineoplastic agent, as a model drug. The results of loading and release studies
were similar to the previously reported literature. Herein the introduction of the
molecular docking technique establishes a method to fast select an effective
β-cyclodextrin-based surface coating for the development of high-performance
magnetic nanoparticles (Chen et al. 2019).
During the last decade, researchers published numerous designings and preparation techniques of cyclodextrin-functionalized superparamagnetic nanoparticles by
conjugating cyclodextrin units onto the surface of magnetite nanoparticles.
Similarly, in one of the notable contributions, Lu and co-workers have explained an
innovative protocol for the development of cyclodextrin-based magnetic nanoparticles intending to establish their wide variety of biomedical applications as targeted
drug delivery vehicles. Briefly, Li et al. (2011) fabricated superparamagnetic
β-cyclodextrin-functionalized composite nanoparticles with core-shell compositions via cross-linking reaction (by using epichlorohydrin as cross-linking agent) on
the surface of carboxymethyl β-cyclodextrin-modified magnetite nanoparticles.
This strategy ensures that the innermost magnetite nanoparticles could sense and
react to an externally applied magnetic field. Additionally, the outermost cyclodextrin moiety represents an inclusion site for drugs. Luo et al. (2012) developed a
novel redox responsive controlled drug release system based on magnetic nanoparticles to provide efficient intracellular anticancer drug delivery. Disulfide bonds are
employed as intermediate linkers to immobilize polyethylenimine/β-cyclodextrin
molecules as nanoreservoirs for drug loading onto magnetic nanoparticles. The
endocytotic pathway and endosomal escape of the smart controlled drug release
system are proposed as an end result. Badruddoza et al. (2013) synthesized highly
uniform silica-coated iron oxide (Fe 3 O 4 ) magnetic nanoparticles and cross-linked
them with carboxymethylated-β-cyclodextrin, intending to equip magnetic nanoparticles with drug storage and delivery carrier. These magnetic nanoparticles contributed quadruple features of magnetism, luminescence, cell targeting, and hydrophobic
drug delivery. These magnetic nanoparticles included functionalities of fluorescence
labeling by fluorescent dye-conjugated and a common cancer-targeting ligand, folic
acid, that Banerjee’s magnetic nanoparticles lacked. Preliminary outcomes of this
study recommend that such magnetic nanoparticles can be a smart theranostic candidate for an optically trackable, cancer cell-targeting, and delivery vehicle of the
hydrophobic drug delivery (all-trans-retinoic acid), loaded in cyclodextrin moiety.
Ding et al. (2015) developed a novel hydrogel of poorly soluble drug 5-fluorouracil,
based on chitosan-cross-linked carboxymethyl-β-cyclodextrin polymer-modified
Fe 3 O 4 magnetic nanoparticles intending to explore the inclusion abilities of cyclodextrin hydrophobic cavity with this insoluble anticancer drug through host-guest
interactions. Experimental results showed that the nanocarriers displayed a high
loading efficiency and pH-dependent swelling and diffusion-controlled drug release.
This report tentatively proposed the mechanism of 5-fluorouracil encapsulated into
the magnetic chitosan nanoparticles.
The literature reveals that the Food and Drug Administration has approved more
than 150 chemotherapeutic agents for cancer treatment. But, most of these drugs
exert cytotoxic action on tumors as well as normal cells and cause severe adverse
A. Pandey